Abstract: Osunprotafib, also known as ABBV-CLS-484 (AC484), is a first-in-class, orally bioavailable, small-molecule active-site inhibitor of the protein tyrosine phosphatases PTPN2 and PTPN1. Traditionally considered undruggable due to their highly polar active sites, these phosphatases act as critical negative regulators of inflammation and immune cell activation. By inhibiting PTPN2 and PTPN1, Osunprotafib amplifies Janus kinase (JAK) and signal transducer and activator of transcription (STAT) signaling, thereby sensitizing tumor cells to interferon-gamma (IFNγ) and unleashing robust anti-tumor immunity mediated by CD8+ T cells and natural killer (NK) cells. Preclinical evaluations demonstrate its potent efficacy across various tumor models, including those resistant to PD-1 blockade, and highlight its potential in treating hematological malignancies, as evidenced by extensive screening in hematopoietic cancer cell lines and efficacy in the EL4-OVA adoptive cell therapy model. Currently in Phase I clinical trials, Osunprotafib represents a major breakthrough in phosphatase-targeted cancer immunotherapy.
1. Introduction
While immune checkpoint blockade has revolutionized cancer therapy, a significant proportion of patients remain refractory to current immunotherapies, necessitating the discovery of novel therapeutic targets to overcome resistance [1]. The protein tyrosine phosphatases PTPN2 (TC-PTP) and its paralogue PTPN1 (PTP-1B) have emerged as central checkpoints of inflammation. They negatively regulate several cytokine signaling pathways and T cell receptor (TCR) signaling by dephosphorylating members of the JAK and STAT families [1]. Genetic deletion of PTPN2 or PTPN1 in either tumor cells or immune cells has been shown to profoundly promote anti-tumor immunity [1] [2].
Despite their biological validation, phosphatases have historically been challenging drug targets. Their highly polar active sites require highly polar inhibitors to drive enzymatic potency, which typically results in compounds with weak cellular activity and poor pharmacokinetic properties, rendering them unsuitable for in vivo therapeutic use [1]. Overcoming these hurdles, researchers have discovered Osunprotafib (ABBV-CLS-484 or AC484), a potent, orally bioavailable small-molecule inhibitor that targets the highly homologous active sites of both PTPN2 and PTPN1 [1]. Osunprotafib is currently being evaluated in Phase I clinical trials (e.g., NCT04777994, NCT04417465) for patients with advanced solid tumors, marking it as the first active-site phosphatase inhibitor to enter clinical evaluation for cancer immunotherapy [1] [2].
2. Pharmacological Activity
Osunprotafib exhibits exceptional biochemical potency, inhibiting PTPN2 and PTPN1 with half-maximal inhibitory concentrations (IC50) of 1.60–1.8 nM and 1.84–2.5 nM, respectively [1] [2]. In cellular assays, it demonstrates significant activity, such as an IC50 of 176 nM for enhancing IFNγ-induced STAT1 phosphorylation in B16 melanoma cells [1]. The compound is highly selective for PTPN2/N1, showing 6- to 8-fold weaker activity on PTPN9 and no detectable activity on SHP-1, SHP-2, or a wide panel of other kinases and receptors [1].
In vivo, systemic oral administration of Osunprotafib induces potent tumor regression and increases survival across multiple syngeneic mouse models, including B16 melanoma, KPC pancreatic adenocarcinoma, CT26 colon cancer, and PD-1-resistant 4T1 and EMT-6 breast carcinomas [1]. Furthermore, it effectively controls metastatic dissemination in pulmonary metastasis models [1].
Regarding hematological malignancies, the PRISM viability screen of Osunprotafib included 97 hematopoietic cancer cell lines, demonstrating its broad applicability across liquid tumors [1]. Additionally, the compound's efficacy was validated in the EL4-OVA adoptive cell therapy model, a well-known murine lymphoma model. In this setting, adoptive transfer of OT-I CD8+ T cells expanded in vitro in the presence of Osunprotafib significantly controlled EL4-OVA tumor growth and improved survival, underscoring its therapeutic potential in hematological contexts [1].
3. Molecular Mechanism of Action
The primary mechanism of action of Osunprotafib involves the dual inhibition of PTPN2 and PTPN1, which normally dampen inflammation by dephosphorylating JAK and STAT proteins. By blocking these phosphatases, Osunprotafib amplifies JAK-STAT signaling cascades, leading to a dual anti-cancer mechanism that acts directly on tumor cells and simultaneously hyperactivates immune effector cells [1].
In tumor cells, Osunprotafib sensitizes the cells to IFNγ. This sensitization leads to profound growth arrest and a robust induction of interferon-stimulated genes (ISGs). Consequently, there is an upregulation of MHC class I antigen presentation and an increased production of T cell chemoattractants, such as CXCL9 and CXCL10, which inflame the tumor microenvironment [1].
In the immune compartment, Osunprotafib enhances the activation, proliferation, and cytotoxicity of CD8+ T cells and NK cells. It lowers the T cell receptor (TCR) activation threshold by increasing the phosphorylation of LCK and FYN kinases [1]. Furthermore, Osunprotafib promotes IL-2-STAT5 signaling in T cells, which drives an epigenetic and transcriptional reprogramming that favors an effector and memory T cell phenotype while significantly reducing the expression of exhaustion markers such as TOX and TIM-3 [1]. The compound also shifts the myeloid compartment towards a pro-inflammatory state, increasing the ratio of M1 to M2 macrophages and activating dendritic cells to produce IL-12 and TNF [1].
4. Structure-Activity Relationship (SAR)
The discovery of Osunprotafib represents a triumph of structure-based drug design over the historically "undruggable" highly polar active sites of phosphatases. The molecule was optimized from earlier thiadiazolidinone dioxide motifs to achieve both low nanomolar enzymatic potency and favorable drug-like properties, including a low molecular weight (<500 Daltons) and good sp3 content [1].
Osunprotafib is a zwitterionic compound, featuring a highly acidic thiadiazolidinone dioxide moiety (NH pKa = 0.9) and a basic amine (NH pKa = 10). This specific zwitterionic character is pivotal for its distinct pharmacokinetic profile, enabling low plasma protein binding (86% unbound in mouse plasma and 50% in human plasma) and low hepatic clearance, with the drug being cleared primarily through renal and biliary mechanisms [1].
Crystallographic analysis of Osunprotafib bound to PTPN2 reveals critical interactions within the active site. The thiadiazolidinone dioxide moiety forms up to nine interactions, including essential hydrogen bonds with residues Cys216, Arg222, Asp182, Ser217, and Ile220 [1]. Additionally, the molecule features a non-planar benzocyclohexane (amino-tetralin) core and an isopentyl-amine (isobutane) side chain. This side chain is specifically designed to engage in a hydrogen bond with Asp50 and a hydrophobic interaction with Met256, further anchoring the inhibitor and driving its high potency and selectivity [1] [2].
5. Current Limitations
While Osunprotafib is highly effective, its mechanism of action inherently relies on intact interferon signaling pathways. Tumors harboring loss-of-function mutations in the IFNγ-sensing pathway—such as mutations in IFNGR1, IFNGR2, JAK, or STAT genes—are significantly enriched among cancer cell lines that are insensitive to Osunprotafib-mediated growth inhibition [1].
Additionally, because PTPN2 and PTPN1 are systemic regulators of inflammation, high doses of Osunprotafib can lead to overt systemic immune activation. In preclinical toxicity studies, doses of 100 mg/kg twice daily in mice led to significant increases in circulating cytotoxic Granzyme B+ CD8+ T cells and systemic cytokines. In rats, high doses (300 mg/kg/day) caused dose-dependent immune cell infiltrates in the kidneys, joints, and liver. However, a major advantage of this small-molecule approach is that these inflammatory infiltrates are completely reversible and resolve rapidly upon cessation of treatment due to the drug's relatively short half-life [1].
6. Future Perspectives
Osunprotafib (ABBV-CLS-484) paves the way for a new class of intracellular immune regulators in cancer immunotherapy. Its ability to achieve efficacy comparable to, or exceeding, that of antibody-based immune checkpoint blockade in preclinical models highlights its immense therapeutic potential [1]. Because it operates through a distinct mechanism—enhancing JAK-STAT signaling and activating multiple cytotoxic immune subsets (both T cells and NK cells)—it holds promise for treating tumors that are resistant to standard PD-1 blockade, including those with impaired MHC class I expression [1].
Future clinical and preclinical investigations will likely focus on combination strategies, such as pairing Osunprotafib with anti-PD-1 therapies, which has already shown additive efficacy in murine models [1]. Furthermore, given the robust activation of T cells and the inclusion of hematopoietic cell lines in initial viability screens, exploring the efficacy of Osunprotafib in hematological malignancies—such as lymphomas and leukemias—represents a highly promising research direction. The successful clinical translation of Osunprotafib may ultimately validate the active sites of phosphatases as a rich, untapped vein for future immunotherapeutic drug discovery [1].
